
Eric J. Sherman, MD, discussed the effects of using the MEK inhibitor trametinib in combination with paclitaxel in metastatic anaplastic thyroid cancer.
Your AI-Trained Oncology Knowledge Connection!
Head and Neck Cancer Chair
Medical Oncology
Head and Neck Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Eric J. Sherman, MD, is a medical oncologist in New York, New York and is affiliated with Memorial Sloan Kettering Cancer Center. Sherman received his medical degree from Columbia University College of Physicians & Surgeons and has been in practice for more than 20 years while dedicated to improving the lives of patients with head and neck cancer. Sherman’s primary clinical and research focus is on thyroid cancers and squamous cell carcinomas of the head and neck. He also has a vast interest in diagnosing and treating the less common cancers of the head and neck, such as sinonasal undifferentiated carcinomas and salivary gland tumors.
Eric J. Sherman, MD, discussed the effects of using the MEK inhibitor trametinib in combination with paclitaxel in metastatic anaplastic thyroid cancer.
Eric J. Sherman, MD, examines the phase 3 COSMIC-311 trial with cabozantinib in radioiodine-refractory differentiated thyroid cancer.
Eric J. Sherman, MD, highlights trends he observed with immunotherapy in the head and neck cancer space.
Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.